Literature DB >> 7776318

Pressure on communication of results of clinical research: potential for improper practice. Proceedings of a meeting. London, October 13, 1993.

.   

Abstract

In earlier times, clinical researchers published the results of their studies as seemed most appropriate to them. In an increasingly computerized and communicative environment this is no longer satisfactory, since now there are a number of other groups whose interests need to be taken into account. These include patients, medical journals, the Stock Exchange, the media and the law. This supplement arises out of a meeting established to describe the methods used to communicate clinical research results, the timing and the needs of other groups in an attempt to improve understanding and to identify preferred practice. Avoidance by clinical investigators of conflict of interest and accusations of improper practice clearly merit discussion.

Entities:  

Mesh:

Year:  1995        PMID: 7776318      PMCID: PMC1295037     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN: 0141-0768            Impact factor:   5.344


  6 in total

1.  The Ingelfinger Rule revisited.

Authors:  M Angell; J P Kassirer
Journal:  N Engl J Med       Date:  1991-11-07       Impact factor: 91.245

2.  More on the Ingelfinger rule.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1988-04-28       Impact factor: 91.245

3.  Financial conflicts of interest in biomedical research.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

4.  Understanding financial conflicts of interest.

Authors:  D F Thompson
Journal:  N Engl J Med       Date:  1993-08-19       Impact factor: 91.245

5.  The Ingelfinger Rule.

Authors:  A S Relman
Journal:  N Engl J Med       Date:  1981-10-01       Impact factor: 91.245

6.  Inappropriate publication of trial results and potential for allegations of illegal share dealing.

Authors:  D S Freestone; H Mitchell
Journal:  BMJ       Date:  1993-04-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.